Summarized by Masters of Longevity from BioSpace - Funding.
An early‑phase trial will test combining two FDA‑approved TKIs to overcome resistance.
Key Takeaways
- The trial will combine osimertinib with alectinib to prevent resistance.
- Alectinib is being repurposed to inhibit FER in drug‑tolerant persister cells.
- Early‑phase funding has been awarded but clinical benefit remains unproven.
